aTyr Pharma, Inc. (NASDAQ:LIFE) will be issuing its Q3 2017 quarterly earnings data on Monday, November 13th. Analysts expect the company to announce earnings of ($0.50) per share for the quarter.

aTyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.51) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.57) by $0.06. On average, analysts expect aTyr Pharma to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Shares of aTyr Pharma, Inc. (NASDAQ:LIFE) opened at $3.95 on Friday. aTyr Pharma, Inc. has a fifty-two week low of $2.10 and a fifty-two week high of $6.50. The company has a current ratio of 6.13, a quick ratio of 6.13 and a debt-to-equity ratio of 0.29.

LIFE has been the topic of a number of recent analyst reports. ValuEngine cut shares of aTyr Pharma from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Zacks Investment Research cut shares of aTyr Pharma from a “buy” rating to a “hold” rating and set a $5.25 target price on the stock. in a report on Thursday, September 28th. Piper Jaffray Companies assumed coverage on shares of aTyr Pharma in a report on Thursday, September 7th. They issued an “overweight” rating and a $7.00 target price on the stock. Finally, BMO Capital Markets set a $4.00 target price on shares of aTyr Pharma and gave the stock a “hold” rating in a report on Tuesday, August 15th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the stock. aTyr Pharma has an average rating of “Hold” and a consensus price target of $4.62.

In related news, CEO John Mendlein bought 37,736 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The shares were bought at an average price of $2.65 per share, for a total transaction of $100,000.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Paul Schimmel bought 94,336 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The stock was bought at an average price of $2.65 per share, for a total transaction of $249,990.40. Following the acquisition, the director now directly owns 40,440 shares of the company’s stock, valued at approximately $107,166. The disclosure for this purchase can be found here. Company insiders own 33.30% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.dailypolitical.com/2017/11/10/atyr-pharma-inc-life-set-to-announce-quarterly-earnings-on-monday.html.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Earnings History for aTyr Pharma (NASDAQ:LIFE)

Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.